Figure 4

Testing the effect of TMPRSS2 inhibitors on SARS-CoV-2 replication in IEC#17. (A) IEC#17 monolayers were treated with either DMSO or 0.1 µM or 10 µM camostat and nafamostat for 1 h. After incubation, the pretreated cells were infected with SARS-CoV-2 at an MOI of 0.1. The supernatants of infected IEC#17 were collected at 48 hpi. SARS-CoV-2 titers were measured by determining the TCID₅₀. Each value is representative of at least three independent experiments and is shown as the mean ± SD from three wells of supernatants of each culture group. The significant differences were determined using one-way ANOVA. The significant differences were determined using one-way ANOVA. (B) IEC#17 monolayers were untreated or treated with DMSO, 10 µM camostat and nafamostat for 1 h. After incubation, the pretreated cells were infected with 2 × 10⁶ genome equivalents of norovirus GII.4. The supernatants of infected IEC#17 cells were collected at 3 and 72 hpi. The viral RNA copies of norovirus GII.4 in IEC#17 were measured by qRT-PCR. Each value is representative of at least three independent experiments and is shown as the mean ± SD from between four and six wells of supernatants of each culture group. The significant differences were determined using one-way ANOVA. *0.01 < P < 0.05.